BRPI0821397B1 - uso de um material calibrador, método para calibrar um imunoensaio para a detecção de auto-anticorpos, e, kit de imunoensaio - Google Patents
uso de um material calibrador, método para calibrar um imunoensaio para a detecção de auto-anticorpos, e, kit de imunoensaio Download PDFInfo
- Publication number
- BRPI0821397B1 BRPI0821397B1 BRPI0821397A BRPI0821397A BRPI0821397B1 BR PI0821397 B1 BRPI0821397 B1 BR PI0821397B1 BR PI0821397 A BRPI0821397 A BR PI0821397A BR PI0821397 A BRPI0821397 A BR PI0821397A BR PI0821397 B1 BRPI0821397 B1 BR PI0821397B1
- Authority
- BR
- Brazil
- Prior art keywords
- calibration
- fluid
- antigen
- autoantibodies
- fact
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims description 137
- 238000003018 immunoassay Methods 0.000 title claims description 62
- 238000000034 method Methods 0.000 title claims description 55
- 238000001514 detection method Methods 0.000 title claims description 39
- 239000000427 antigen Substances 0.000 claims description 152
- 108091007433 antigens Proteins 0.000 claims description 152
- 102000036639 antigens Human genes 0.000 claims description 152
- 239000012530 fluid Substances 0.000 claims description 139
- 206010028980 Neoplasm Diseases 0.000 claims description 99
- 210000001124 body fluid Anatomy 0.000 claims description 70
- 239000010839 body fluid Substances 0.000 claims description 69
- 238000010790 dilution Methods 0.000 claims description 67
- 239000012895 dilution Substances 0.000 claims description 67
- 210000004910 pleural fluid Anatomy 0.000 claims description 60
- 201000011510 cancer Diseases 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 206010003445 Ascites Diseases 0.000 claims description 32
- 210000000416 exudates and transudate Anatomy 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 230000009870 specific binding Effects 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 238000002835 absorbance Methods 0.000 claims 2
- 240000007124 Brassica oleracea Species 0.000 claims 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims 1
- 210000002966 serum Anatomy 0.000 description 73
- 238000012360 testing method Methods 0.000 description 48
- 238000003556 assay Methods 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 40
- 239000000439 tumor marker Substances 0.000 description 34
- 230000027455 binding Effects 0.000 description 26
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 18
- 230000009257 reactivity Effects 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 13
- 230000001900 immune effect Effects 0.000 description 13
- 239000013642 negative control Substances 0.000 description 13
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 12
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 12
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 11
- 102000052609 BRCA2 Human genes 0.000 description 10
- 108700020462 BRCA2 Proteins 0.000 description 10
- 101150008921 Brca2 gene Proteins 0.000 description 10
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 230000009871 nonspecific binding Effects 0.000 description 10
- 229960002685 biotin Drugs 0.000 description 9
- 235000020958 biotin Nutrition 0.000 description 9
- 239000011616 biotin Substances 0.000 description 9
- 238000011088 calibration curve Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 239000010836 blood and blood product Substances 0.000 description 8
- 229940125691 blood product Drugs 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 208000002151 Pleural effusion Diseases 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 6
- 201000002528 pancreatic cancer Diseases 0.000 description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 6
- 102000000412 Annexin Human genes 0.000 description 5
- 108050008874 Annexin Proteins 0.000 description 5
- 108090000663 Annexin A1 Proteins 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108090000668 Annexin A2 Proteins 0.000 description 4
- 108010039627 Aprotinin Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 229960004405 aprotinin Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102100040006 Annexin A1 Human genes 0.000 description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 3
- 101000617550 Dictyostelium discoideum Presenilin-A Proteins 0.000 description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010040102 Seroma Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 206010020488 hydrocele Diseases 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000026872 Addison Disease Diseases 0.000 description 2
- 102000004145 Annexin A1 Human genes 0.000 description 2
- 102000004149 Annexin A2 Human genes 0.000 description 2
- 102100034613 Annexin A2 Human genes 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101100508538 Homo sapiens IKBKE gene Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102100021857 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Human genes 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000954 titration curve Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 208000020176 autoimmune hypoparathyroidism Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000007392 microtiter assay Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0725239.8A GB0725239D0 (en) | 2007-12-24 | 2007-12-24 | Calibrator for autoantibody assay |
| US1668907P | 2007-12-26 | 2007-12-26 | |
| PCT/GB2008/004260 WO2009081165A1 (en) | 2007-12-24 | 2008-12-23 | Calibrator for immunoassays |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0821397A2 BRPI0821397A2 (pt) | 2017-05-23 |
| BRPI0821397B1 true BRPI0821397B1 (pt) | 2018-10-09 |
Family
ID=39092384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0821397A BRPI0821397B1 (pt) | 2007-12-24 | 2008-12-23 | uso de um material calibrador, método para calibrar um imunoensaio para a detecção de auto-anticorpos, e, kit de imunoensaio |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20090176319A1 (enExample) |
| EP (1) | EP2223114B1 (enExample) |
| JP (1) | JP5594776B2 (enExample) |
| CN (1) | CN101952723B (enExample) |
| AU (1) | AU2008339624B2 (enExample) |
| BR (1) | BRPI0821397B1 (enExample) |
| CA (1) | CA2707025C (enExample) |
| CY (1) | CY1118253T1 (enExample) |
| DK (1) | DK2223114T3 (enExample) |
| ES (1) | ES2588731T3 (enExample) |
| GB (1) | GB0725239D0 (enExample) |
| HR (1) | HRP20161109T1 (enExample) |
| IL (1) | IL205733A (enExample) |
| PT (1) | PT2223114T (enExample) |
| SG (1) | SG186684A1 (enExample) |
| SI (1) | SI2223114T1 (enExample) |
| WO (1) | WO2009081165A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9810040D0 (en) * | 1998-05-11 | 1998-07-08 | Univ Nottingham | Blood borne tumour markers |
| GB9827228D0 (en) * | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
| US20030232399A1 (en) * | 2000-06-14 | 2003-12-18 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
| GB2424070B (en) * | 2002-11-14 | 2007-06-27 | Univ Nottingham | Methods for preparing tumour marker proteins |
| US7858323B2 (en) | 2004-06-09 | 2010-12-28 | The Regents Of The University Of Michigan | Phage microarray profiling of the humoral response to disease |
| NZ563466A (en) | 2005-05-27 | 2009-12-24 | Oncimmune Ltd | Improved immunoassay methods |
| GB2426581A (en) * | 2005-05-27 | 2006-11-29 | Univ Nottingham | Immunoassay methods |
| WO2007136025A1 (ja) * | 2006-05-19 | 2007-11-29 | Bml, Inc. | 感染症の検出方法 |
| CN101632020B (zh) | 2006-09-13 | 2013-11-27 | 昂西免疫有限公司 | 改进的免疫测定方法 |
| GB0725239D0 (en) * | 2007-12-24 | 2008-02-06 | Oncimmune Ltd | Calibrator for autoantibody assay |
| WO2011116209A2 (en) | 2010-03-17 | 2011-09-22 | The Regents Of The University Of Michigan | Using phage epitopes to profile the immune response |
| US11662564B2 (en) | 2017-06-15 | 2023-05-30 | Shenzhen Prs Limited | Paraffin shield coating for microscope slide |
| WO2018228577A1 (en) * | 2017-06-15 | 2018-12-20 | Sunstone Scientific Limited. | Method for ihc antigen imaging scale extrapolation |
| US12313834B2 (en) | 2017-06-15 | 2025-05-27 | Shenzhen Prs Limited | Paraffin shield coating for microscope slide |
| BR102021003012A2 (pt) | 2020-02-19 | 2021-11-30 | Univ Berlin Charite | Métodos para o diagnóstico de infecção por sars-cov-2, kit e usos |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4241044A (en) * | 1978-12-28 | 1980-12-23 | Abbott Laboratories | Method of diagnosing cancer by detecting elevated anti-T antibody activity |
| JPS60192263A (ja) * | 1984-03-13 | 1985-09-30 | Teijin Ltd | 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法 |
| NZ211453A (en) * | 1984-03-22 | 1989-01-06 | Biotechnology Research Enterpr | Aryl azides, their preparation and use in the detection, localisation and isolation of polynucleotides |
| US4937185A (en) * | 1987-07-31 | 1990-06-26 | The Ohio State University Research Foundation | Detection of circulating antibodies to a cancer marker protein |
| US7282345B1 (en) * | 1989-08-04 | 2007-10-16 | Schering Ag | C-erbB-2 external domain: GP75 |
| US5110911A (en) * | 1989-11-02 | 1992-05-05 | Biomira, Inc. | Human tumor-associated thomsen-friedenreich antigen |
| US5157020A (en) * | 1990-05-24 | 1992-10-20 | Research Corporation Tech., Inc. | Synthetic senescent cell antigen |
| DE4120412C1 (enExample) * | 1991-06-20 | 1993-01-07 | Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De | |
| JPH067191A (ja) * | 1991-09-26 | 1994-01-18 | Konica Corp | モノクローナル抗体、それを産生するハイブリド−マ、その対応抗原及びそれを用いた測定方法 |
| US6322989B1 (en) * | 1991-11-25 | 2001-11-27 | Yoreh Biotechnologies, Ltd. | Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit |
| US6280962B1 (en) * | 1991-11-25 | 2001-08-28 | Yoreh Biotechnologies Ltd. | Whole blood/mitogen assay for the early detection of a subject with cancer and kit |
| ATE408012T1 (de) * | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| EP0625909A4 (en) * | 1992-02-12 | 1997-03-05 | Robert Perper | Autoantibody assay and usage in the control of human disease. |
| WO1993021529A1 (en) * | 1992-04-14 | 1993-10-28 | Duke University | Method of detecting tumors containing complexes of p53 and hsp70 |
| US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US5763164A (en) * | 1993-04-16 | 1998-06-09 | Northwestern University | Immunogenic cancer proteins and peptides and methods of use |
| US5747268A (en) * | 1993-04-22 | 1998-05-05 | Dade International Inc. | Tumor marker control |
| US5744144A (en) * | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| US5721105A (en) * | 1994-02-20 | 1998-02-24 | B.R.A.H.M.S. Diagnostica Gmbh | Method for the immunological determination of proteins and kit for carrying out the method |
| US5789655A (en) * | 1994-05-13 | 1998-08-04 | The Regents Of The University Of California | Transgenic animals expressing artificial epitope-tagged proteins |
| US5561049A (en) * | 1994-09-21 | 1996-10-01 | Behringwerke Ag | Method for detecting antibodies |
| US5876728A (en) * | 1995-02-15 | 1999-03-02 | Howard David Kass | Natural composition extracted from plants used in the treatment of cancer |
| US5723343A (en) * | 1995-08-28 | 1998-03-03 | University Of Florida | Autoantibodies in patients with acquired hypoparathyroidism and assay method therefor |
| JP3472048B2 (ja) * | 1995-10-09 | 2003-12-02 | 鐘淵化学工業株式会社 | 自己免疫疾患の診断薬 |
| WO1998006746A2 (en) * | 1996-08-16 | 1998-02-19 | The Johns Hopkins University School Of Medicine | Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same |
| US6306636B1 (en) * | 1997-09-19 | 2001-10-23 | Arch Development Corporation | Nucleic acid segments encoding wheat acetyl-CoA carboxylase |
| DE19805815C1 (de) * | 1998-02-13 | 1999-11-11 | Ansgar W Lohse | Diagnostikum zum Erkennen der autoimmunen Hepatitis |
| US6388062B1 (en) * | 1998-05-08 | 2002-05-14 | The Wistar Institute Of Anatomy And Biology | Modified p53 tetramerization domains having hydrophobic amino acid substitutions |
| GB9810040D0 (en) * | 1998-05-11 | 1998-07-08 | Univ Nottingham | Blood borne tumour markers |
| JP3268494B2 (ja) * | 1998-10-01 | 2002-03-25 | 俊成 広畑 | 全身性エリテマトーデス病態診断剤 |
| US6387639B1 (en) * | 1998-11-10 | 2002-05-14 | Sloan-Kettering Institute For Cancer Research | Ma family polypeptides and anti-Ma antibodies |
| GB9827228D0 (en) * | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
| US7807810B2 (en) * | 1999-04-08 | 2010-10-05 | The Ohio State University Research Foundation | Nucleic acids encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby |
| US6645465B2 (en) * | 1999-08-06 | 2003-11-11 | Michigan, University Of The Regents | Annexin proteins and autoantibodies as serum markers for cancer |
| DE19939575C1 (de) * | 1999-08-20 | 2001-08-02 | Orgentec Diagnostika Gmbh | Verfahren zur Diagnose von Sjögren-Syndrom |
| US20020064801A1 (en) * | 1999-12-01 | 2002-05-30 | Ryan Jeffrey R. | Novel and practical serological assay for the clinical diagnosis of leishmaniasis |
| US6667160B2 (en) * | 2000-03-15 | 2003-12-23 | Kenneth D. Fine | Method for diagnosing immunologic food sensitivity |
| AU4465001A (en) * | 2000-03-30 | 2001-10-15 | Nippon Kayaku Kabushiki Kaisha | Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor |
| US20030232399A1 (en) * | 2000-06-14 | 2003-12-18 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
| US20030138860A1 (en) * | 2000-06-14 | 2003-07-24 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
| WO2003073101A2 (en) * | 2001-06-21 | 2003-09-04 | New York University | Mycobacterial proteins as early antigens for serodiagnosis and vaccines |
| US20030049692A1 (en) * | 2002-09-16 | 2003-03-13 | Norman Latov | Detection of anti-glycolipid antibodies by latex agglutination assay |
| GB2424070B (en) * | 2002-11-14 | 2007-06-27 | Univ Nottingham | Methods for preparing tumour marker proteins |
| WO2004063226A2 (en) * | 2002-12-27 | 2004-07-29 | Applied Research Systems Ars Holding N.V. | Novel fibrillin-like polypeptides |
| JP2005352771A (ja) * | 2004-06-10 | 2005-12-22 | Hitachi Software Eng Co Ltd | 発現プロファイルによるパターン認識システム |
| US20060141547A1 (en) * | 2004-11-16 | 2006-06-29 | Das Hasi R | Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis |
| GB2426581A (en) * | 2005-05-27 | 2006-11-29 | Univ Nottingham | Immunoassay methods |
| EP1789435B1 (en) * | 2005-09-12 | 2010-02-24 | Industry Foundation of Chonnam National University | A method for production of mature natural killer cell |
| TWI304443B (en) * | 2005-12-30 | 2008-12-21 | Nat Health Research Institutes | Alpha-enolase specific antibody and method of use |
| CN101632020B (zh) * | 2006-09-13 | 2013-11-27 | 昂西免疫有限公司 | 改进的免疫测定方法 |
| AU2007297310B2 (en) * | 2006-09-13 | 2013-11-07 | Oncimmune Limited | Improved immunoassay methods |
| GB0725239D0 (en) * | 2007-12-24 | 2008-02-06 | Oncimmune Ltd | Calibrator for autoantibody assay |
| GB201411060D0 (en) * | 2014-06-20 | 2014-08-06 | Oncimmune Ltd | Improved immunoassay method |
-
2007
- 2007-12-24 GB GBGB0725239.8A patent/GB0725239D0/en not_active Ceased
-
2008
- 2008-12-23 BR BRPI0821397A patent/BRPI0821397B1/pt not_active IP Right Cessation
- 2008-12-23 PT PT88652649T patent/PT2223114T/pt unknown
- 2008-12-23 DK DK08865264.9T patent/DK2223114T3/en active
- 2008-12-23 JP JP2010538909A patent/JP5594776B2/ja not_active Expired - Fee Related
- 2008-12-23 SG SG2012095006A patent/SG186684A1/en unknown
- 2008-12-23 AU AU2008339624A patent/AU2008339624B2/en not_active Ceased
- 2008-12-23 US US12/343,047 patent/US20090176319A1/en not_active Abandoned
- 2008-12-23 CN CN200880122385.1A patent/CN101952723B/zh not_active Expired - Fee Related
- 2008-12-23 ES ES08865264.9T patent/ES2588731T3/es active Active
- 2008-12-23 CA CA2707025A patent/CA2707025C/en active Active
- 2008-12-23 SI SI200831684A patent/SI2223114T1/sl unknown
- 2008-12-23 HR HRP20161109TT patent/HRP20161109T1/hr unknown
- 2008-12-23 EP EP08865264.9A patent/EP2223114B1/en not_active Not-in-force
- 2008-12-23 WO PCT/GB2008/004260 patent/WO2009081165A1/en not_active Ceased
-
2010
- 2010-05-13 IL IL205733A patent/IL205733A/en active IP Right Grant
-
2016
- 2016-09-23 US US15/274,012 patent/US20170074884A1/en not_active Abandoned
- 2016-11-17 CY CY20161101189T patent/CY1118253T1/el unknown
-
2020
- 2020-11-19 US US16/952,473 patent/US20210318320A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK2223114T3 (en) | 2016-10-24 |
| HRP20161109T1 (hr) | 2016-11-04 |
| GB0725239D0 (en) | 2008-02-06 |
| AU2008339624B2 (en) | 2014-11-20 |
| AU2008339624A1 (en) | 2009-07-02 |
| HK1152380A1 (zh) | 2012-02-24 |
| EP2223114B1 (en) | 2016-08-17 |
| US20090176319A1 (en) | 2009-07-09 |
| CA2707025A1 (en) | 2009-07-02 |
| BRPI0821397A2 (pt) | 2017-05-23 |
| JP2011508197A (ja) | 2011-03-10 |
| SI2223114T1 (sl) | 2016-11-30 |
| WO2009081165A1 (en) | 2009-07-02 |
| ES2588731T3 (es) | 2016-11-04 |
| CA2707025C (en) | 2020-08-25 |
| PT2223114T (pt) | 2016-09-29 |
| IL205733A (en) | 2014-09-30 |
| SG186684A1 (en) | 2013-01-30 |
| JP5594776B2 (ja) | 2014-09-24 |
| EP2223114A1 (en) | 2010-09-01 |
| CY1118253T1 (el) | 2017-06-28 |
| US20210318320A1 (en) | 2021-10-14 |
| US20170074884A1 (en) | 2017-03-16 |
| CN101952723A (zh) | 2011-01-19 |
| CN101952723B (zh) | 2016-05-11 |
| IL205733A0 (en) | 2010-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0821397B1 (pt) | uso de um material calibrador, método para calibrar um imunoensaio para a detecção de auto-anticorpos, e, kit de imunoensaio | |
| Nilsen et al. | Development of quantitative vitellogenin-ELISAs for fish test species used in endocrine disruptor screening | |
| Cummings et al. | Biomarker method validation in anticancer drug development | |
| Englebienne et al. | High-throughput screening using the surface plasmon resonance effect of colloidal gold nanoparticles | |
| Punchoo et al. | Variation in the measurement of anti-Müllerian hormone–what are the laboratory issues? | |
| ES2681238T3 (es) | Medios y métodos de aplicación de la relación sFlt-1/PIGF o Endoglina/PIGF para descartar la aparición de preeclampsia en un cierto periodo de tiempo | |
| ES2650263T3 (es) | Dinámica de la razón de SFLT-1 o endoglina/PLGF como indicador para preeclampsia inminente y/o síndrome de HELLP | |
| Einhorn et al. | HTRF: a technology tailored for biomarker determination—novel analytical detection system suitable for detection of specific autoimmune antibodies as biomarkers in nanogram level in different body fluids | |
| WO2024055498A1 (zh) | 一种能定量检定人载脂蛋白apoc1的检测试剂盒及其检测方法 | |
| KR101794403B1 (ko) | 쇼그렌증후군 특이적 항체반응 검사를 이용한 쇼그렌증후군 진단방법 | |
| ES2685831T3 (es) | Predicción del síndrome de HELLP postparto, de la eclampsia postparto, o de la preeclampsia postparto | |
| EP3045916A1 (en) | Kit and method for diagnosis, prognosis or monitoring of liver disease through measurement of amount of ast | |
| Thaler et al. | Biosensor analyses of serum autoantibodies: application to antiphospholipid syndrome and systemic lupus erythematosus | |
| WO2011099435A1 (ja) | Ｋｕ８６とその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法 | |
| Clouet-Foraison et al. | Standardization of Analytical Methods for the Measurement of Lipoprotein (a): Bridging Past and Future Initiatives | |
| EP3604517A1 (en) | Anti-apoa1 antibody | |
| CN117434276A (zh) | 一种thsd7a抗体检测试剂盒及其用途 | |
| Willis et al. | Solid phase immunoassay for the detection of anticardiolipin antibodies | |
| Willis et al. | Solid phase immunoassay for the detection of anti-β2 glycoprotein I antibodies | |
| Korponay-Szabó et al. | Development of Cell-Assembled Human Endomysial-Type Biomatrix Substrate for the Detection of Celiac Disease Autoantibodies | |
| Herries et al. | Brain biomarkers: follow-up of RNA expression discovery approach: CSF assays for neurogranin, SNAP-25, and VILIP-1 | |
| HK1152380B (en) | Calibrator for immunoassays | |
| JP5504945B2 (ja) | Ｆｔｃｄとその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法 | |
| CN107857815A (zh) | 与糖肽反应的单克隆抗体及其用途 | |
| WO2023068249A1 (ja) | Ｉ型コラーゲン架橋ｎ－テロペプチドの測定試薬、その調製方法、及びそれを用いた免疫測定方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2008, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2755 DE 24-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |